leadership team
Meet the Lipid Management Team
Our team of industry leaders at ESPERION has proven expertise in understanding cholesterol biosynthesis. Our team combines excellence in drug development with superior business skills, demonstrating a commitment to providing patients and physicians new oral therapies to reduce LDL-C.

The Lipid Management Team at ESPERION has deep and broad relationships with other industry-leading experts and businesses, enabling them to extend their impact where and when needed.

Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010.

Prior to joining ESPERION, Tim was President, Chief Executive Officer, and a director of Vericel Corporation, formerly Aastrom Biosciences, Inc.

Previously, Tim was President, Chief Operating Officer, and a director of NightHawk Radiology Holdings, Inc. Prior to joining NightHawk, Tim was the Chief Operating Officer of the original ESPERION, until its acquisition by Pfizer in 2004.

Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, LOXO Oncology, Marinus Pharmaceuticals, and the Wolverine Venture Fund.

Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

Rick Bartram is Chief Financial Officer. Prior to joining ESPERION, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm.

Rick earned an MS in Accounting from Michigan State University and a BA, with honor, in accounting from Michigan State University. Rick is also a Certified Public Accountant.

Regina Cavaliere is Chief Ethics and Compliance Officer.

Prior to joining ESPERION, Regina was a Principal at KPMG, LLP providing regulatory and compliance advice to life science clients. She previously served as Chief Compliance Officer at Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc.  She was VP of Healthcare Compliance at Alpharma and held legal and compliance roles at Bristol-Myers Squibb Company. She practiced law in New York City prior to her tenure in industry.

She brings over 25 years of legal and compliance experience supporting the pharmaceutical industry.  She speaks regularly at industry compliance conferences and is an instructor at Seton Hall Law’s Health Care Compliance Certification Program (HCCP) and HCCP-Plus.

Regina holds a BA magna cum laude from Seton Hall University and a JD from Rutgers School of Law – Newark.

Mark Glickman is Chief Commercial Officer.

Prior to joining Esperion, Mark served as Chief Commercial Officer at Aralez Pharmaceuticals Inc.

He previously served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals, Vice President in the medical device division at Otsuka America Pharmaceutical, Inc., and President of Sales at Bayer Healthcare’s Diabetes Care Division.

He has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions, and organizational expansions.

Mark holds a Master of Business Administration degree from New York University.

Ashley Hall is Chief Development Officer.

Prior to joining ESPERION, Ashley was Global Regulatory Lead for Cardiovascular at Amgen and oversaw the regulatory strategy and global filings for the evolocumab program, leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering.

Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012.

Prior to joining Micromet, Ashley was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune.

Ashley held various roles of increasing responsibility in global regulatory affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company.

Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute.

Ashley earned a Juris Doctorate at the University of San Diego School of Law and a Bachelor of Science in Biochemistry and Cell Biology at the University of California San Diego.

Ken is Senior Vice President of Technical Operations.

Prior to joining ESPERION, Ken was a consultant to start-ups and mid-size companies focused on CMC strategies, NDA preparation and launch readiness.

Previously, he served as VP Manufacturing at NPS Pharmaceuticals. Prior to NPS, Ken served as VP Technical Operations at Otsuka America Pharmaceuticals for five years and was responsible for US supply chain, clinical supplies, US-CMC Development, QC and Packaging Technologies.

Before Otuska, Ken served as VP Manufacturing and Supply Chain at Cephalon. Previously, he was at BMS for seventeen years in development and manufacturing roles and at JNJ for five years.

Ken is a Pharmacist and holds a BS, MS and PhD in Pharmaceutical Sciences from Rutgers University.

Bill Sasiela is Senior Vice President of Clinical Development.

Prior to joining ESPERION, Bill was a consultant in the pharmaceutical industry.

Previously, he was the Vice President of Program Direction-Cardiovascular Metabolism at Regeneron Pharmaceuticals from 2010 to 2017.

Prior to joining Regeneron Pharmaceuticals, Bill served as Chief Medical Officer at Aegerion Pharmaceuticals from 2005 to 2010.

Bill has worked in senior clinical/medical roles at Pfizer and Parke-Davis.

Bill earned a PhD from the University of South Carolina School of Medicine and a BS in Biochemistry from Virginia Polytechnic.

All trademarks are the property of their respective owners.